In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection

Abstract Clostridioides difficile infections (CDIs) are an urgent public health threat worldwide and are a leading cause of morbidity and mortality in healthcare settings. The increasing incidence and severity of infections combined with the scarcity of effective anti-CDI agents has made treatment o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nader S. Abutaleb, Mohamed N. Seleem
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/0da84e67d61c438098f83388cd104305
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0da84e67d61c438098f83388cd104305
record_format	dspace
spelling	oai:doaj.org-article:0da84e67d61c438098f83388cd1043052021-12-02T14:23:13ZIn vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection10.1038/s41598-021-86595-32045-2322https://doaj.org/article/0da84e67d61c438098f83388cd1043052021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86595-3https://doaj.org/toc/2045-2322Abstract Clostridioides difficile infections (CDIs) are an urgent public health threat worldwide and are a leading cause of morbidity and mortality in healthcare settings. The increasing incidence and severity of infections combined with the scarcity of effective anti-CDI agents has made treatment of CDI very challenging. Therefore, development of new, effective anticlostridial agents remains a high priority. The current study investigated the in vivo efficacy of auranofin in a CDI hamster model. All hamsters treated with auranofin (5 mg/kg) survived a lethal challenge with C. difficile. Furthermore, auranofin (5 mg/kg) was as effective as vancomycin, the drug of choice for treatment of CDIs, against relapsing CDI. Furthermore, auranofin (5 mg/kg) generated a 3.15-log10 reduction (99.97%) in C. difficile count in the cecal contents of hamsters. These results indicate that auranofin warrants further investigation as a new agent to replenish the pipeline of anti-CDI therapeutics.Nader S. AbutalebMohamed N. SeleemNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Nader S. Abutaleb Mohamed N. Seleem In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection
description	Abstract Clostridioides difficile infections (CDIs) are an urgent public health threat worldwide and are a leading cause of morbidity and mortality in healthcare settings. The increasing incidence and severity of infections combined with the scarcity of effective anti-CDI agents has made treatment of CDI very challenging. Therefore, development of new, effective anticlostridial agents remains a high priority. The current study investigated the in vivo efficacy of auranofin in a CDI hamster model. All hamsters treated with auranofin (5 mg/kg) survived a lethal challenge with C. difficile. Furthermore, auranofin (5 mg/kg) was as effective as vancomycin, the drug of choice for treatment of CDIs, against relapsing CDI. Furthermore, auranofin (5 mg/kg) generated a 3.15-log10 reduction (99.97%) in C. difficile count in the cecal contents of hamsters. These results indicate that auranofin warrants further investigation as a new agent to replenish the pipeline of anti-CDI therapeutics.
format	article
author	Nader S. Abutaleb Mohamed N. Seleem
author_facet	Nader S. Abutaleb Mohamed N. Seleem
author_sort	Nader S. Abutaleb
title	In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection
title_short	In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection
title_full	In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection
title_fullStr	In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection
title_full_unstemmed	In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection
title_sort	in vivo efficacy of auranofin in a hamster model of clostridioides difficile infection
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/0da84e67d61c438098f83388cd104305
work_keys_str_mv	AT nadersabutaleb invivoefficacyofauranofininahamstermodelofclostridioidesdifficileinfection AT mohamednseleem invivoefficacyofauranofininahamstermodelofclostridioidesdifficileinfection
_version_	1718391409422106624

In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection

Ejemplares similares